300942 易瑞生物
已收盘 05-08 15:00:00
资讯
新帖
简况
每周股票复盘：易瑞生物（300942）2025年营收2.63亿净利1374万
证券之星 · 05-03
每周股票复盘：易瑞生物（300942）2025年营收2.63亿净利1374万
易瑞生物：2025年度利润承压主要受战略性投入增加等综合影响
中金财经 · 04-30
易瑞生物：2025年度利润承压主要受战略性投入增加等综合影响
易瑞生物（300942）2026年一季报简析：增收不增利，三费占比上升明显
证券之星 · 04-28
易瑞生物（300942）2026年一季报简析：增收不增利，三费占比上升明显
易瑞生物（300942）披露董事、高级管理人员薪酬管理制度，4月27日股价下跌4.82%
证券之星 · 04-27
易瑞生物（300942）披露董事、高级管理人员薪酬管理制度，4月27日股价下跌4.82%
易瑞生物(300942)3月31日股东户数1.75万户，较上期增加1.69%
证券之星 · 04-26
易瑞生物(300942)3月31日股东户数1.75万户，较上期增加1.69%
图解易瑞生物年报：第四季度单季净利润同比下降132.37%
证券之星 · 04-26
图解易瑞生物年报：第四季度单季净利润同比下降132.37%
易瑞生物：公司能为客户提供覆盖饲料、养殖、生产、加工、流通、零售等各个环节的检测解决方案
证券之星 · 04-17
易瑞生物：公司能为客户提供覆盖饲料、养殖、生产、加工、流通、零售等各个环节的检测解决方案
易瑞生物（300942）披露2026年第一季度可转债转股情况，4月3日股价下跌4.4%
证券之星 · 04-03
易瑞生物（300942）披露2026年第一季度可转债转股情况，4月3日股价下跌4.4%
易瑞生物：实际控制人对公司经营状况与发展前景充满信心
证券之星 · 02-05
易瑞生物：实际控制人对公司经营状况与发展前景充满信心
易瑞生物（300942）披露副总经理辞职公告，2月3日股价上涨2.63%
证券之星 · 02-03
易瑞生物（300942）披露副总经理辞职公告，2月3日股价上涨2.63%
易瑞生物最新公告：副总经理陈智英因个人原因辞职
中金财经 · 02-03
易瑞生物最新公告：副总经理陈智英因个人原因辞职
2月2日易瑞生物发布公告，股东减持334.5万股
证券之星 · 02-02
2月2日易瑞生物发布公告，股东减持334.5万股
易瑞生物新注册《食用油掺伪现场快速鉴别系统V1.0》项目的软件著作权
证券之星 · 01-31
易瑞生物新注册《食用油掺伪现场快速鉴别系统V1.0》项目的软件著作权
1月26日易瑞生物现1笔折价12.15%的大宗交易 合计成交219.42万元
证券之星 · 01-26
1月26日易瑞生物现1笔折价12.15%的大宗交易 合计成交219.42万元
股市必读：1月20日易瑞生物现1笔大宗交易 机构净买入273万元
证券之星 · 01-21
股市必读：1月20日易瑞生物现1笔大宗交易 机构净买入273万元
股市必读：1月19日易瑞生物现1笔折价11.94%的大宗交易 合计成交270万元
证券之星 · 01-20
股市必读：1月19日易瑞生物现1笔折价11.94%的大宗交易 合计成交270万元
股市必读：1月12日易瑞生物现1笔折价13.43%的大宗交易 合计成交203.09万元
证券之星 · 01-13
股市必读：1月12日易瑞生物现1笔折价13.43%的大宗交易 合计成交203.09万元
易瑞生物：公司目前暂无脑机接口相关领域的业务布局
证券之星 · 01-06
易瑞生物：公司目前暂无脑机接口相关领域的业务布局
易瑞生物（300942）披露2025年第四季度可转债转股情况，1月5日股价上涨4.25%
证券之星 · 01-05
易瑞生物（300942）披露2025年第四季度可转债转股情况，1月5日股价上涨4.25%
股市必读：12月25日易瑞生物现2笔折价13.13%的大宗交易 合计成交688万元
证券之星 · 2025-12-26
股市必读：12月25日易瑞生物现2笔折价13.13%的大宗交易 合计成交688万元
加载更多
公司概况
公司名称：
深圳市易瑞生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2021-02-09
主营业务：
深圳市易瑞生物技术股份有限公司的主营业务是食品安全快速检测业务。公司的主要产品是胶体金免疫层析试纸、酶联免疫（ELISA）试剂盒、理化试剂、荧光PCR试剂盒、核酸提取试剂盒。
发行价格：
5.31
{"stockData":{"symbol":"300942","market":"SZ","secType":"STK","nameCN":"易瑞生物","latestPrice":7.89,"timestamp":1778223783000,"preClose":7.82,"halted":0,"volume":5312332,"delay":0,"changeRate":0.009,"floatShares":405000000,"shares":405000000,"eps":0.0169,"marketStatus":"已收盘","change":0.07,"latestTime":"05-08 15:00:00","open":7.82,"high":7.95,"low":7.79,"amount":41887700,"amplitude":0.0205,"askPrice":7.89,"askSize":4,"bidPrice":7.88,"bidSize":45,"shortable":0,"etf":0,"ttmEps":0.0169,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":7.82,"symbolType":"stock","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":8.6,"lowLimit":7.04,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":405068876,"isCdr":false,"pbRate":3.81,"roa":"--","peRate":466.863905,"roe":"--","epsLYR":0.03,"committee":0.176062,"marketValue":3196000000,"turnoverRate":0.0131,"status":0,"floatMarketCap":3196000000},"requestUrl":"/m/hq/s/300942","defaultTab":"news","newsList":[{"id":"2632670710","title":"每周股票复盘：易瑞生物（300942）2025年营收2.63亿净利1374万","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670710","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670710?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:33","pubTimestamp":1777764790,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，易瑞生物报收于7.89元，较上周的8.3元下跌4.94%。本周，易瑞生物4月27日盘中最高价报8.09元。易瑞生物当前最新总市值31.96亿元，在医疗器械板块市值排名107/129，在两市A股市值排名4512/5200。业绩披露要点2025年度公司实现营业收入26,322.90万元，同比增长17.38%；归属于母公司股东的净利润为1,374.33万元，同比下降19.71%。公司2023年亏损，2024年扭亏为盈，2025年收入增长但净利润下降。持续督导期内可转债尚未完全转股，保荐机构将继续履行后续职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631683326","title":"易瑞生物：2025年度利润承压主要受战略性投入增加等综合影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2631683326","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631683326?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:40","pubTimestamp":1777534857,"startTime":"0","endTime":"0","summary":"证券之星消息，易瑞生物04月29日在投资者关系平台上答复投资者关心的问题。2025年度，公司深耕主业，在国内外市场同步推进，食品安全快速检测板块以及动物诊断板块营业收入均实现增长。而公司实现的利润规模同比有所承压，主要受市场拓展等战略性投入持续增加，可转债利息、对外投资等非经营性事项扰动，及其他相关因素的综合影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260430/32193854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630346370","title":"易瑞生物（300942）2026年一季报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2630346370","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630346370?lang=zh_cn&edition=full","pubTime":"2026-04-28 06:55","pubTimestamp":1777330517,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期易瑞生物发布2026年一季报。本报告期易瑞生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达39.63%。去年的净利率为5.88%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800022749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630980193","title":"易瑞生物（300942）披露董事、高级管理人员薪酬管理制度，4月27日股价下跌4.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630980193","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630980193?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:59","pubTimestamp":1777287599,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，易瑞生物报收于7.9元，较前一交易日下跌4.82%，最新总市值为32亿元。该股当日开盘8.09元，最高8.09元，最低7.4元，成交额达1.22亿元，换手率为3.93%。近日，深圳市易瑞生物技术股份有限公司发布《董事、高级管理人员薪酬管理制度》公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700035913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630384315","title":"易瑞生物(300942)3月31日股东户数1.75万户，较上期增加1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630384315","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630384315?lang=zh_cn&edition=full","pubTime":"2026-04-26 17:14","pubTimestamp":1777194880,"startTime":"0","endTime":"0","summary":"证券之星消息，近日易瑞生物披露，截至2026年3月31日公司股东户数为1.75万户，较12月31日增加291.0户，增幅为1.69%。在医疗器械行业个股中，易瑞生物股东户数低于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.19万户。从股价来看，2025年12月31日至2026年3月31日，易瑞生物区间跌幅为10.73%，在此期间股东户数增加291.0户，增幅为1.69%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600011325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630812203","title":"图解易瑞生物年报：第四季度单季净利润同比下降132.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630812203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630812203?lang=zh_cn&edition=full","pubTime":"2026-04-26 17:00","pubTimestamp":1777194029,"startTime":"0","endTime":"0","summary":"证券之星消息，易瑞生物2025年年报显示，当年度公司主营收入2.63亿元，同比上升17.38%；归母净利润1374.33万元，同比下降19.71%；扣非净利润-965.32万元，同比下降442.68%；其中2025年第四季度，公司单季度主营收入7759.54万元，同比上升17.21%；单季度归母净利润-427.97万元，同比下降132.37%；单季度扣非净利润-1338.17万元，同比下降265.38%；负债率40.46%，投资收益-814.56万元，财务费用1753.61万元，毛利率63.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600010374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628820223","title":"易瑞生物：公司能为客户提供覆盖饲料、养殖、生产、加工、流通、零售等各个环节的检测解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2628820223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628820223?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:57","pubTimestamp":1776387427,"startTime":"0","endTime":"0","summary":"证券之星消息，易瑞生物(300942)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：清明假期又兼五一长假，易瑞生物检测是否在食品检测中大展身手？易瑞生物回复：尊敬的投资者，您好。公司能为客户提供覆盖饲料、养殖、生产、加工、流通、零售等各个环节的检测解决方案。公司将积极响应市场需求，助力市场各环节保障食品安全。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700010081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624565409","title":"易瑞生物（300942）披露2026年第一季度可转债转股情况，4月3日股价下跌4.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624565409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624565409?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:04","pubTimestamp":1775214241,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，易瑞生物报收于8.04元，较前一交易日下跌4.4%，最新总市值为32.57亿元。该股当日开盘8.39元，最高8.44元，最低8.04元，成交额达4827.07万元，换手率为1.46%。公司近日披露《关于2026年第一季度可转债转股情况的公告》。公告显示，2026年第一季度，“易瑞转债”因转股减少10张，转股数量为112股。截至2026年3月31日，尚有2,908,268张可转债未转股，剩余票面总金额为290,826,800元。公司总股本由405,068,764股增至405,068,876股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300036329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609298933","title":"易瑞生物：实际控制人对公司经营状况与发展前景充满信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609298933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609298933?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:15","pubTimestamp":1770275724,"startTime":"0","endTime":"0","summary":"证券之星消息，易瑞生物02月05日在投资者关系平台上答复投资者关心的问题。至此，实控人累计质押股份为890万股。按照行业惯例，质押股份券商最多六折给付，而且质押股份还能转融通二次做空。实际控制人对公司经营状况与发展前景充满信心，本次股权质押是基于其自身资金需求和规划，不会对公司日常生产经营产生影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500018990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608287708","title":"易瑞生物（300942）披露副总经理辞职公告，2月3日股价上涨2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608287708","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608287708?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:42","pubTimestamp":1770129744,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，易瑞生物报收于9.77元，较前一交易日上涨2.63%，最新总市值为39.58亿元。公告显示，深圳市易瑞生物技术股份有限公司董事会于近日收到副总经理陈智英女士的书面辞职报告，陈智英女士因个人原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。其工作已按规定交接，辞职报告自送达董事会之日起生效。截至公告日，陈智英女士及其直系亲属未直接或间接持有公司股份，不存在应履行而未履行的承诺事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300043431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608128824","title":"易瑞生物最新公告：副总经理陈智英因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2608128824","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608128824?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:04","pubTimestamp":1770113067,"startTime":"0","endTime":"0","summary":"易瑞生物(300942.SZ)公告称，公司董事会近日收到副总经理陈智英的书面辞职报告，陈智英因个人原因申请辞去副总经理职务。原定任期至第三届董事会届满之日止，辞职后不再担任公司任何职务。陈智英已完成工作交接，其辞职报告自送达董事会之日起生效。截至公告披露日，陈智英及其直系亲属未持有公司股份，也无应履行而未履行的承诺事项。公司对陈智英的贡献表示感谢。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260203/31995211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608851866","title":"2月2日易瑞生物发布公告，股东减持334.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851866","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851866?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:01","pubTimestamp":1770033689,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日易瑞生物发布公告《易瑞生物:关于控股股东及其一致行动人减持计划期限届满暨减持结果的公告》，其股东深圳易凯瑞管理咨询合伙企业(有限合伙)、易瑞(海南)创业投资有限公司、深圳易达瑞管理咨询合伙企业(有限合伙)于2026年1月6日至2026年1月29日间合计减持334.5万股，占公司目前总股本的0.8257%，变动期间该股股价上涨0.61%，截止1月29日收盘报9.87元。股东增减持详情见下表：根据易瑞生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200034489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607025536","title":"易瑞生物新注册《食用油掺伪现场快速鉴别系统V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025536?lang=zh_cn&edition=full","pubTime":"2026-01-31 02:28","pubTimestamp":1769797692,"startTime":"0","endTime":"0","summary":"证券之星消息，近日易瑞生物（300942）新注册了《食用油掺伪现场快速鉴别系统V1.0》项目的软件著作权。今年以来易瑞生物新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1959.78万元，同比减2.6%。通过天眼查大数据分析，深圳市易瑞生物技术股份有限公司共对外投资了23家企业，参与招投标项目840次；财产线索方面有商标信息55条，专利信息163条，著作权信息27条；此外企业还拥有行政许可88个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606219823","title":"1月26日易瑞生物现1笔折价12.15%的大宗交易 合计成交219.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219823","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606219823?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:17","pubTimestamp":1769422656,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日易瑞生物发生大宗交易，交易数据如下：大宗交易成交价格9.54元，相对当日收盘价折价12.15%，成交23万股，成交金额219.42万元，买方营业部为机构专用，卖方营业部为东兴证券股份有限公司上海陆家嘴证券营业部。近三个月该股共发生20笔大宗交易，合计成交6.73万手，折价成交20笔。该股近期无解禁股上市。截至2026年1月26日收盘，易瑞生物报收于10.86元，上涨5.33%，换手率5.83%，成交量23.6万手，成交额2.54亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605145177","title":"股市必读：1月20日易瑞生物现1笔大宗交易 机构净买入273万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605145177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605145177?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:21","pubTimestamp":1768936863,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘，易瑞生物报收于10.1元，下跌1.17%，换手率1.71%，成交量6.94万手，成交额7029.74万元。当日关注点来自交易信息汇总：1月20日主力资金净流出258.55万元，散户资金净流入110.06万元。大宗交易1月20日易瑞生物现1笔大宗交易，机构净买入273万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100002585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604130046","title":"股市必读：1月19日易瑞生物现1笔折价11.94%的大宗交易 合计成交270万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604130046","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604130046?lang=zh_cn&edition=full","pubTime":"2026-01-20 02:35","pubTimestamp":1768847711,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，易瑞生物报收于10.22元，上涨1.09%，换手率1.2%，成交量4.87万手，成交额4974.92万元。当日关注点来自交易信息汇总：1月19日主力资金净流入325.07万元，呈现资金主动介入迹象。来自交易信息汇总：同日发生一笔折价11.94%的大宗交易，合计成交270万元，值得关注后续动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000000981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603528534","title":"股市必读：1月12日易瑞生物现1笔折价13.43%的大宗交易 合计成交203.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603528534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603528534?lang=zh_cn&edition=full","pubTime":"2026-01-13 02:29","pubTimestamp":1768242548,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，易瑞生物报收于10.2元，上涨1.69%，换手率1.9%，成交量7.7万手，成交额7791.26万元。来自交易信息汇总：同日发生一笔折价13.43%的大宗交易，合计成交203.09万元，需关注后续是否存在持续减持动向。交易信息汇总资金流向1月12日主力资金净流入501.1万元；游资资金净流出408.34万元；散户资金净流出92.76万元。大宗交易1月12日易瑞生物现1笔折价13.43%的大宗交易，合计成交203.09万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300942"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601850426","title":"易瑞生物：公司目前暂无脑机接口相关领域的业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2601850426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601850426?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:33","pubTimestamp":1767670435,"startTime":"0","endTime":"0","summary":"证券之星消息，易瑞生物(300942)01月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司是否有布局脑机接口相关领域的业务…易瑞生物回复：尊敬的投资者，您好。公司目前暂无脑机接口相关领域的业务布局。感谢您的关注!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600015707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601880842","title":"易瑞生物（300942）披露2025年第四季度可转债转股情况，1月5日股价上涨4.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601880842","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601880842?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:45","pubTimestamp":1767624323,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，易瑞生物报收于9.81元，较前一交易日上涨4.25%，最新总市值为39.74亿元。近日，深圳市易瑞生物技术股份有限公司发布关于2025年第四季度可转债转股情况的公告。2025年第四季度，易瑞转债因转股减少14张，转股数量为157股。截至2025年12月31日，易瑞转债尚有2,908,278张，剩余票面总金额为290,827,800元。公司总股本由405,068,607股增至405,068,764股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594255522","title":"股市必读：12月25日易瑞生物现2笔折价13.13%的大宗交易 合计成交688万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594255522","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594255522?lang=zh_cn&edition=full","pubTime":"2025-12-26 02:43","pubTimestamp":1766688189,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，易瑞生物报收于9.9元，上涨3.66%，换手率3.16%，成交量12.8万手，成交额1.26亿元。当日关注点来自交易信息汇总：12月25日主力与游资资金均呈净流入态势，合计达1625.52万元，而散户资金净流出1625.51万元。来自交易信息汇总：当日发生2笔大宗交易，合计成交688万元，折价率达13.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600000881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300942","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778447289124,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.075},{"period":"3month","weight":-0.1965},{"period":"6month","weight":-0.2557},{"period":"1year","weight":-0.1563},{"period":"ytd","weight":-0.1615}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市易瑞生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17527人(较上一季度增加1.69%)","perCapita":"23111股","listingDate":"2021-02-09","address":"广东省深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园2栋A101","registeredCapital":"40506万元","survey":" 深圳市易瑞生物技术股份有限公司的主营业务是食品安全快速检测业务。公司的主要产品是胶体金免疫层析试纸、酶联免疫（ELISA）试剂盒、理化试剂、荧光PCR试剂盒、核酸提取试剂盒。","listedPrice":5.31},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"易瑞生物(300942)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供易瑞生物(300942)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"易瑞生物,300942,易瑞生物股票,易瑞生物股票老虎,易瑞生物股票老虎国际,易瑞生物行情,易瑞生物股票行情,易瑞生物股价,易瑞生物股市,易瑞生物股票价格,易瑞生物股票交易,易瑞生物股票购买,易瑞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"易瑞生物(300942)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供易瑞生物(300942)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}